Drug updated on 11/15/2023
| Dosage Form | Capsule (oral: 50 mg, 75 mg) |
| Drug Class | Farnesyltransferase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above to reduce risk of mortality in Hutchinson-Gilford progeria syndrome.
- Indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above for treatment of processing-deficient progeroid laminopathies with heterozygous LMNA mutation with progerin-like protein accumulation.
- Indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above for treatment of processing-deficient progeroid laminopathies with homozygous or compound heterozygous ZMPSTE24 mutations.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zokinvy (lonafarnib) Prescribing Information. | 2020 | Eiger BioPharmaceuticals Inc., Palo Alto, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Zonkinvy. | 2022 | EMA |